ASCO 2026: SENOMAC Supports Omission of Completion Axillary Dissection

Primary endpoint results from the randomized SENOMAC trial were presented by Jana de Boniface, MD, PhD, Adjunct Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, and Surgeon at Capio Saint Göran's Hospital, Stockholm, Sweden, at the ASCO 2026 Congress. in this MEDtalk Jana de Boniface discusses the impact of omitting completion axillary lymph node dissection (ALND) in patients with breast cancer and sentinel lymph node macrometastases, demonstrating non-inferior overall survival and reduced patient-reported arm morbidity.